You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model

Article info

Article menu

This article has a correction. Please see:

XML
Basic tumor immunology
Original research
Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model

Authors

  • Jing Wen Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USAUCLA AIDS Institute, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Lan Wang Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USAUCLA AIDS Institute, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Jie Ren Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Emiko Kranz Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USAUCLA AIDS Institute, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Shilin Chen Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Di Wu Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Toshio Kanazawa Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USAUCLA AIDS Institute, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Irvin Chen Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USAUCLA AIDS Institute, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Yunfeng Lu Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Masakazu Kamata Microbiology, University of Alabama at Birmingham School of Arts and Humanities, Birmingham, Alabama, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Masakazu Kamata; masa3k{at}uab.edu
View Full Text

Citation

Wen J, Wang L, Ren J, et al
Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
Journal for ImmunoTherapy of Cancer 2021;9:e001524. doi: 10.1136/jitc-2020-001524

Publication history

  • Accepted December 17, 2020
  • First published February 16, 2021.
Online issue publication 
January 26, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.